Core Viewpoint - Recently, the National Organization for Drug Procurement Office announced the results of the national centralized drug procurement, in which the company and its subsidiary, Shandong Lukang Pharmaceutical Group Saiter Co., Ltd., have won bids for certain drugs [1] Group 1 - The company, Lukang Pharmaceutical (600789.SH), has been selected in the recent centralized procurement process [1] - The procurement results were published in a notification regarding the national centralized drug procurement (GY-YD2025-1) [1] - The subsidiary involved in the procurement is Shandong Lukang Pharmaceutical Group Saiter Co., Ltd. [1]

Core Viewpoint - The announcement indicates that the company and its subsidiary have successfully won bids in the national centralized drug procurement, which is expected to contribute significantly to their revenue in the upcoming years [1] Group 1: Procurement Results - The company and its subsidiary, Shandong Lukang Pharmaceutical Group Set Co., Ltd., have been selected for the national centralized procurement of drugs [1] - The total sales revenue from the selected products for the year 2024 is projected to be 405 million yuan, accounting for approximately 6.49% of the company's total revenue for that year [1] - For the first half of 2025, the expected sales revenue from these products is 225 million yuan, representing about 7.14% of the company's revenue for that period [1]